Tharimmune, Inc. Files 8-K with Material Agreement
Ticker: CNTN · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1861657
| Field | Detail |
|---|---|
| Company | Tharimmune, INC. (CNTN) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $0.001, $3.16, $3.09, $2.08 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-action, filing
Related Tickers: THAR
TL;DR
Tharimmune (THAR) signed a big deal on 6/18, filing an 8-K. Details TBD.
AI Summary
On June 18, 2024, Tharimmune, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company also reported other events and filed financial statements and exhibits. Tharimmune, Inc. was formerly known as Hillstream BioPharma Inc. and changed its name on September 25, 2023.
Why It Matters
This filing indicates a significant development for Tharimmune, Inc. through a material definitive agreement, suggesting potential strategic shifts or operational changes that could impact its future business and financial performance.
Risk Assessment
Risk Level: medium — The filing reports a material definitive agreement, which could involve significant business changes, but the lack of specific details in this 8-K introduces uncertainty.
Key Players & Entities
- Tharimmune, Inc. (company) — Registrant
- June 18, 2024 (date) — Date of earliest event reported
- Hillstream BioPharma Inc. (company) — Former company name
- September 25, 2023 (date) — Date of name change
- 001-41210 (other) — Commission File Number
FAQ
What is the nature of the Material Definitive Agreement entered into by Tharimmune, Inc. on June 18, 2024?
The filing states that Tharimmune, Inc. entered into a Material Definitive Agreement on June 18, 2024, but the specific terms and details of this agreement are not provided in this current report.
What other items are reported in this 8-K filing besides the Material Definitive Agreement?
In addition to the entry into a Material Definitive Agreement, the filing also reports on 'Other Events' and 'Financial Statements and Exhibits'.
When did Tharimmune, Inc. change its name from Hillstream BioPharma Inc.?
Tharimmune, Inc. changed its name from Hillstream BioPharma Inc. on September 25, 2023.
What is Tharimmune, Inc.'s principal executive office address?
Tharimmune, Inc.'s principal executive offices are located at 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807.
What is the SIC code for Tharimmune, Inc.?
The Standard Industrial Classification (SIC) code for Tharimmune, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 846 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2024-06-20 16:15:17
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value THAR The Nasdaq Stock Mar
- $0.001 — 's Common Stock at an exercise price of $0.001 per share and warrants (the " Common Wa
- $3.16 — 's Common Stock, at a purchase price of $3.16 per share of Common Stock (or common st
- $3.09 — ate of issuance at an exercise price of $3.09 per share and have a term of exercise e
- $2.08 m — cement are expected to be approximately $2.08 million, before deducting placement agent
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex4-1.htm (EX-4.1) — 111KB
- ex4-2.htm (EX-4.2) — 107KB
- ex10-1.htm (EX-10.1) — 231KB
- ex99-1.htm (EX-99.1) — 17KB
- 0001493152-24-024516.txt ( ) — 780KB
- thar-20240618.xsd (EX-101.SCH) — 3KB
- thar-20240618_lab.xml (EX-101.LAB) — 33KB
- thar-20240618_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 20, 2024 Tharimmune, Inc. /s/ Randy Milby Randy Milby Chief Executive Officer -3-